Alamar Biosciences Inc.

5 days ago · globenewswire.com

Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations

25 days ago · seekingalpha.com

Alamar Biosciences is rated a buy, targeting a recurring consumables-driven model with expansion into clinical diagnostics. 2Q26 revenue surged 82% YoY to $29.4M, with consumables up 147% and now exceeding half of total revenue. Gross margin improved to 60% on manufacturing efficiencies and consumables mix, but high operating expenses maintain losses amid aggressive investment.

1 month ago · globenewswire.com

Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab

3 months ago · seekingalpha.com

Alamar Biosciences is building a content-driven proteomics platform, with accelerating consumables revenue and expanding biomarker panels driving long-term growth. Q2 2026 revenue grew 82% YoY to $29.4M, with consumables sales up 147% and gross margin rising to 60%, highlighting improving revenue quality and operational leverage potential. ALMR's installed base enables capital-efficient expansion, with new assays deployable across existing instruments, creating workflow stickiness and recurring revenue opportunities.